Today we announced interim Phase 1/2a clinical data for ARO-MAPT. The results represent an important step in clinical validation of our TRiM platform for delivering siRNA to the central nervous system. Join today’s webinar to learn more: bit.ly/3VMXyCD

The FDA has granted plozasiran entry into the Split Real Time Application Review (STAR) pilot program for severe hypertriglyceridemia (sHTG), qualifying the supplemental application for 6-month priority review vs the 10-month standard review. Learn more: bit.ly/4dtDqLU

We’re in Orlando through October 4 for #NLAFall. Our teams are excited to share the latest in our cardiometabolic advances at Booth 202.

Join Arrowhead leadership and experts on Oct. 14th for an R&D webinar discussing our CNS pipeline and interim clinical data from the Phase 1/2 study of ARO-MAPT. Learn more and register for the event: bit.ly/3VeYijK

We're pleased to announce positive interim data from the Phase 1/2a study of our investigational dual-functional RNAi therapeutic, ARO-DIMER-PA, supporting our novel approach for the treatment of cardiometabolic disease. Learn more here: bit.ly/4AfEtIZ

Arrowhead Pharmaceuticals will be participating in several investor conferences this month. Members of our leadership team will share updates on our RNAi pipeline and key clinical programs. Details on presentation times and webcast links can be found here: bit.ly/4xAWz6n

Breaking News: At the European Society of Cardiology Congress (ESC), we presented Phase 3 SHASTA-3 & SHASTA-4 data demonstrating our investigational siRNA therapy reduced acute pancreatitis events in patients with severe hypertriglyceridemia. Learn more: arrowheadpharma.com/en-us/ne…

News Update: Today we announced that we will present important new data at the upcoming European Society of Cardiology (ESC) on August 30 and 31 in Munich, Germany. Learn more: arrowheadpharma.com/en-us/ne…

People living with FCS in Germany now have access to REDEMPLO® (plozasiran) as a new treatment option. REDEMPLO® is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with FCS. Learn more here: bit.ly/3U4kTim

We are hosting a conference call and webcast today at 4:30 p.m. ET to discuss fiscal 2026 third quarter financial results and provide a corporate update. To learn more or participate in the conference call: bit.ly/4gbSU8P #WeAreArrowhead

We’ve acquired an FDA Rare Pediatric Disease Priority Review Voucher (PRV) to be used for an upcoming sNDA submission for patients with severe hypertriglyceridemia (sHTG) Read the full announcement: bit.ly/3TC7VrU

Arrowhead Pharmaceuticals has completed enrollment in the Phase 3 YOSEMITE study in adolescent and adult patients with homozygous familial hypercholesterolemia (HoFH) Learn more here: bit.ly/4wqwOVO

Breaking News: We’re pleased to announce positive topline results, with our Phase 3 SHASTA-3 and SHASTA-4 studies achieving the primary endpoint and all secondary endpoints in patients living with severe hypertriglyceridemia (sHTG).​ Learn more: businesswire.com/news/home/2…

Arrowhead Pharmaceuticals will host a webcast and conference call to discuss fiscal 2026 third quarter earnings, recent progress, and upcoming milestones. Learn more in today’s press release: bit.ly/4ywRSvf

Reminder: Part I of our 2026 Summer Series of R&D Webinars is TODAY! Tune in to learn more about our cardiometabolic pipeline from external experts and our management team. Register on our website: bit.ly/4eJ4NkF #RNAi #TRiM #Cardiometabolic

We're hosting Part I of our 2026 Summer Series of R&D Webinars beginning with a focus on our #Cardiometabolic pipeline! Tune in to hear presentations from external experts and Arrowhead management. Learn more: bit.ly/3QrXoyg

What an incredible week in Chicago! Thank you to everyone who visited us at #NLASessions and #ENDO2026; the conversations and connections mean everything. We’re leaving ready for what's next.

The work in Chicago continues with #ENDO2026 June 13–16! 🌆 Find us at Booth #3719 to learn more about our data and what we're working on! Come say hello; we look forward to connecting!

Chicago, here we come! We’re joining the lipidology & cardiometabolic health community at #NLASessions, June 11–14 at the Sheraton Grand Chicago Riverwalk. Stop by Booth 202 and say hello! 👋

Arrowhead Pharmaceuticals has announced upcoming participation in two investor conferences this month. For details on the conferences and presentation schedules, please see today’s press release: bit.ly/4g0Gzoe